Asahi Kasei has supplied $1m in a series A extension to bring the total of the series A round, already backed by GC, to $10.5m.
Asahi Kasei Corporate Venture Capital (AKCVC), the investment arm of conglomerate Asahi Kasei, has supplied C$1.3m ($1m) in a series A extension to Canada-based drug developer Feldan Therapeutics.
The second close brings the round’s total to $10.5m after GC, the parent of biopharmaceutical firm GC Pharma, had a led an initial tranche in September this year that also included Stonebridge Ventures, Anges Québec Capital and unnamed, existing investors.
Feldan Therapeutics is working on the direct delivery of proteins and peptides…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
